Aduro Biotech, Inc. (NASDAQ:ADRO) EVP Dirk G. Brockstedt sold 10,000 shares of Aduro Biotech stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $10.59, for a total value of $105,900.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Aduro Biotech, Inc. (NASDAQ ADRO) traded down 0.89% on Wednesday, hitting $11.10. The company had a trading volume of 277,455 shares. The firm’s market capitalization is $828.19 million. Aduro Biotech, Inc. has a 12-month low of $8.75 and a 12-month high of $15.52. The firm has a 50-day moving average price of $11.18 and a 200-day moving average price of $10.94.

Aduro Biotech (NASDAQ:ADRO) last released its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.02). The company had revenue of $5.90 million for the quarter, compared to analyst estimates of $3.98 million. Aduro Biotech had a negative return on equity of 43.92% and a negative net margin of 609.58%. The business’s revenue for the quarter was down 84.9% compared to the same quarter last year. During the same period last year, the company posted $0.03 earnings per share. On average, equities research analysts anticipate that Aduro Biotech, Inc. will post ($1.35) earnings per share for the current fiscal year.

WARNING: “Dirk G. Brockstedt Sells 10,000 Shares of Aduro Biotech, Inc. (ADRO) Stock” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/10/04/dirk-g-brockstedt-sells-10000-shares-of-aduro-biotech-inc-adro-stock-2.html.

A number of research analysts have issued reports on the company. William Blair reissued an “outperform” rating on shares of Aduro Biotech in a report on Monday. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Aduro Biotech in a report on Wednesday, September 27th. BidaskClub cut Aduro Biotech from a “hold” rating to a “sell” rating in a report on Tuesday, August 8th. Canaccord Genuity set a $30.00 price objective on Aduro Biotech and gave the company a “buy” rating in a report on Thursday, August 3rd. Finally, Zacks Investment Research cut Aduro Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $19.00.

A number of large investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc boosted its stake in Aduro Biotech by 11.2% in the second quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 1,043 shares in the last quarter. American International Group Inc. boosted its stake in Aduro Biotech by 7.1% in the first quarter. American International Group Inc. now owns 21,840 shares of the biotechnology company’s stock valued at $235,000 after buying an additional 1,447 shares in the last quarter. Parametric Portfolio Associates LLC boosted its stake in Aduro Biotech by 15.9% in the first quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock valued at $166,000 after buying an additional 2,119 shares in the last quarter. Voya Investment Management LLC boosted its stake in Aduro Biotech by 15.3% in the second quarter. Voya Investment Management LLC now owns 18,935 shares of the biotechnology company’s stock valued at $216,000 after buying an additional 2,515 shares in the last quarter. Finally, Nationwide Fund Advisors boosted its stake in Aduro Biotech by 12.5% in the second quarter. Nationwide Fund Advisors now owns 23,112 shares of the biotechnology company’s stock valued at $263,000 after buying an additional 2,567 shares in the last quarter. 35.05% of the stock is currently owned by institutional investors and hedge funds.

About Aduro Biotech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.